drugset / Trial / NCT07092748
A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase Ia/Ib, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and preliminary efficacy of HS387 in subjects with advanced solid tumors. It includes two parts: the dose escalation study (Phase Ia) and the dose expansion study (Phase Ib)
Timeline
- Start
- 2025-07-15
- Primary completion
- 2028-06-30
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS387 | Unknown | — | Oral |
Indications
No indication recorded.